Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLKB1 | P03952 | 18/20 | 0.70 |
| ▸ | F11 | P03951 | 3/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17785338 | 0.86 | KLKB1 (0.94) | KLKB1F11CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL31339410 | 0.86 | KLKB1 (0.63) | KLKB1F11 | |
| SCHEMBL17785263 | 0.86 | KLKB1 (0.63) | KLKB1F11 | |
| SCHEMBL28379609 | 0.84 | KLKB1 (0.78) | KLKB1F11CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL17785285 | 0.83 | KLKB1 (1.00) | KLKB1CYP3A4CYP2C8CYP2C9 | |
| SCHEMBL19682322 | 0.80 | KLKB1 (0.84) | KLKB1F11 | |
| SCHEMBL17785314 | 0.78 | KLKB1 (0.65) | KLKB1F11 | |
| SCHEMBL28279003 | 0.77 | KLKB1 (0.53) | KLKB1 | |
| SCHEMBL28279023 | 0.76 | KLKB1 (0.53) | KLKB1 | |
| SCHEMBL17785303 | 0.73 | KLKB1 (0.58) | KLKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3556752-B1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-05 | — | — | EP | disclosed |
| CN-113387933-A | Pyrazole derivatives as plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2021-09-14 | — | — | CN | disclosed |
| CN-109311847-B | Pyrazole derivatives as plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2021-07-06 | — | — | CN | disclosed |
| EP-3760622-A1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2021-01-06 | — | — | EP | disclosed |
| EP-3567037-B1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-12-23 | — | — | EP | disclosed |
| EP-3464271-B1 | PYRAZOLE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2020-05-13 | — | — | EP | disclosed |
| CN-107108576-B | N- ((hetero) arylmethyl) -heteroaryl-carboxamide compounds as plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2020-03-10 | — | — | CN | disclosed |
| CN-110577519-A | N- ((hetero) arylmethyl) -heteroaryl-carboxamide compounds as plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2019-12-17 | — | — | CN | disclosed |
| EP-3567037-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2019-11-13 | — | — | EP | disclosed |
| EP-3556752-A1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2019-10-23 | — | — | EP | disclosed |
| EP-3224256-B1 | N-((HET)ARYLMETHYL)-HETEROARYL-CARBOXAMIDES COMPOUNDS AS PLASMA KALLIKREIN INHIBITORS, | KALVISTA PHARMACEUTICALS LTD (GB) | 2019-07-03 | — | — | EP | disclosed |